Giulia Morlino
About Giulia Morlino
Giulia Morlino is a Principal Scientist at BenevolentAI in London, with extensive experience in cardiovascular research and a strong background in immunology and medical biotechnology.
Company
Giulia Morlino currently works at BenevolentAI in London, England, United Kingdom. She joined BenevolentAI in June 2020 as a Principal Scientist. BenevolentAI is a company known for leveraging artificial intelligence to develop new and better medicines, and Morlino's role involves significant contributions in this domain.
Title
Giulia Morlino holds the title of Principal Scientist. In this role, she utilizes her extensive background in cardiovascular research, immunology, and medical biotechnology to advance scientific initiatives at BenevolentAI.
Education and Expertise
Giulia Morlino has a strong educational background in medical biotechnology and immunology. She obtained her Master of Science degree in Medical Biotechnology from Università degli Studi di Napoli Federico II, followed by a PhD in Basic and Applied Immunology from Libera Università Vita-Salute San Raffaele. Her education laid a solid foundation for her research, particularly in cardiovascular sciences and biotechnology.
Background
Giulia Morlino has a rich professional history in both cardiovascular and immunological research. She worked at the Spanish National Center for Cardiovascular Research (CNIC) for a total of seven years, first as a Doctoral Student and later as a Postdoctoral Researcher. Following her time at CNIC, she served as a Postdoctoral Training Fellow at The Francis Crick Institute in London for six years. She has also conducted undergraduate research at the Institute of Genetics and Biophysics-CNR in Naples, Italy.
International Research Experience
Giulia Morlino's career spans multiple countries, underscoring her international research experience. After earning her advanced degrees in Italy, she conducted significant cardiovascular research in Spain at CNIC. She then moved to the United Kingdom to work at The Francis Crick Institute, further diversifying her research portfolio and gaining international recognition.